Vetr upgraded shares of Horizon Pharma Inc. (NASDAQ:HZNP) from a buy rating to a strong-buy rating in a report published on Monday morning.
HZNP has been the subject of several other reports. Goldman Sachs Group Inc. reiterated a buy rating and set a $27.00 price objective on shares of Horizon Pharma in a research report on Thursday, September 8th. Guggenheim reiterated a buy rating and set a $30.00 price objective on shares of Horizon Pharma in a research report on Tuesday, August 23rd. Cowen and Company reiterated an outperform rating and set a $42.00 price objective on shares of Horizon Pharma in a research report on Monday, September 12th. Mizuho increased their price objective on shares of Horizon Pharma from $30.00 to $33.00 and gave the stock a buy rating in a research report on Tuesday, September 13th. Finally, Stifel Nicolaus reiterated a buy rating and set a $45.00 price objective on shares of Horizon Pharma in a research report on Wednesday, July 6th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $30.00.
Horizon Pharma (NASDAQ:HZNP) opened at 19.25 on Monday. The stock’s 50 day moving average is $19.37 and its 200-day moving average is $17.77. Horizon Pharma has a 12 month low of $12.86 and a 12 month high of $23.70. The company’s market capitalization is $3.10 billion.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.12. Horizon Pharma had a negative net margin of 0.34% and a positive return on equity of 23.46%. The company earned $257.40 million during the quarter, compared to analysts’ expectations of $235.43 million. During the same period in the prior year, the company posted $0.39 earnings per share. Horizon Pharma’s revenue for the quarter was up 48.9% compared to the same quarter last year. On average, analysts expect that Horizon Pharma will post $2.15 EPS for the current year.
In related news, EVP Jeffrey W. Sherman sold 2,900 shares of the firm’s stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $20.00, for a total transaction of $58,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.10% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the company. Deerfield Management Co. increased its stake in Horizon Pharma by 17.6% in the first quarter. Deerfield Management Co. now owns 13,740,261 shares of the biopharmaceutical company’s stock worth $227,676,000 after buying an additional 2,055,460 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in Horizon Pharma by 2.7% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 2,337,953 shares of the biopharmaceutical company’s stock worth $38,740,000 after buying an additional 61,457 shares during the period. Creative Planning increased its stake in Horizon Pharma by 43.3% in the second quarter. Creative Planning now owns 27,806 shares of the biopharmaceutical company’s stock worth $458,000 after buying an additional 8,400 shares during the period. Barclays PLC increased its stake in Horizon Pharma by 11,807.2% in the first quarter. Barclays PLC now owns 142,767 shares of the biopharmaceutical company’s stock worth $2,284,000 after buying an additional 141,568 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in Horizon Pharma during the first quarter worth about $114,000. Institutional investors and hedge funds own 85.25% of the company’s stock.
About Horizon Pharma
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.